Bio
Celltrion to co-develop pill-type autoimmune disease drug with UK startup
By Aug 20, 2020 (Gmt+09:00)
1
Min read
Most Read
Korea’s Incheon Airport Corp. signs $3 billion deal to run Manila airport
S.Korea's LS Materials set to boost earnings ahead of IPO process
Samsung Elec vies for Johnson Controls' HVAC units
Samsung to supply $752 million in Mach-1 AI chips to Naver, replace Nvidia
Solo Leveling: Arise, Netmarble's webtoon-based game to spur turnaround
Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Pharma, the South Korean company said on August 20, a move seen as an effort to expand its presence in the monoclonal antibody biosimilar market.
Both companies will develop a pill version of infliximab, the main ingredient of Celltrion’s monoclonal antibody biosimilar Remsima.
The agreement comes after Celltriont developed the world’s first intravenous injection and subcutaneous (SC)-injection types of Remsima, a biosimilar version of Janssen’s Remicade which is also a brand name of infliximab.
Celltrion controls more than half the market of biosimilar versions of Remicade in Europe. The recent introduction of the SC-injection type is expected to help the Korean biosimilar maker increase its market share, given that Janssen and other biosimilar makers have not yet developed the SC-injection type of infliximab.
Under the agreement, Celltrion will supply its infliximab biosimilar as a raw material for clinical trials to Intract Pharma. The UK biotech company will be responsible for the tablet-type development and clinical tests, using its oral immunotherapy technology designed to push the molecules of a drug absorbed into the blood through the intestinal wall.
Celltrion will also secure priority rights over the new development upon completion of second-phase clinical trials. If they transfer the technology to a third company, Celltrion will receive part of the sales as royalties.
Additionally, Celltrion will supply its infliximab biosimilar exclusively to the third company when it succeeds in commercializing the oral-version treatment, using their technology.
Both companies are exempted from first-phase non-clinical and clinical tests for the oral infliximab. Intract Pharma will kick off second-phase clinical trials next year for patients with inflammatory bowel diseases.
Write to Woo-sub Kim at duter@hankyung.com
Both companies will develop a pill version of infliximab, the main ingredient of Celltrion’s monoclonal antibody biosimilar Remsima.
The agreement comes after Celltriont developed the world’s first intravenous injection and subcutaneous (SC)-injection types of Remsima, a biosimilar version of Janssen’s Remicade which is also a brand name of infliximab.
Celltrion controls more than half the market of biosimilar versions of Remicade in Europe. The recent introduction of the SC-injection type is expected to help the Korean biosimilar maker increase its market share, given that Janssen and other biosimilar makers have not yet developed the SC-injection type of infliximab.
Under the agreement, Celltrion will supply its infliximab biosimilar as a raw material for clinical trials to Intract Pharma. The UK biotech company will be responsible for the tablet-type development and clinical tests, using its oral immunotherapy technology designed to push the molecules of a drug absorbed into the blood through the intestinal wall.
Celltrion will also secure priority rights over the new development upon completion of second-phase clinical trials. If they transfer the technology to a third company, Celltrion will receive part of the sales as royalties.
Additionally, Celltrion will supply its infliximab biosimilar exclusively to the third company when it succeeds in commercializing the oral-version treatment, using their technology.
Both companies are exempted from first-phase non-clinical and clinical tests for the oral infliximab. Intract Pharma will kick off second-phase clinical trials next year for patients with inflammatory bowel diseases.
Write to Woo-sub Kim at duter@hankyung.com
Yeonhee Kim edited this article
More to Read
-
Shipping & ShipbuildingHD Hyundai Heavy wins record $463 million warship deal from Peru’s Navy
28 MINUTES AGO
Comment 0
LOG IN